Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in adult aHUS patients naive to complement inhibitor therapy
2023-508840-22-00Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of Iptacopan in atypical hemolytic uremic syndrome (aHUS), sponsored by Novartis. Primary endpoint: Complete thrombotic microangiopathy (TMA) response without use of plasma exchange/plasma infusion and anti-C5 antibody during 26 weeks of study treatment. Started Jul 2024; status: completed.
02
Drugs
Iptacopan
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on 2023-508840-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508840-22-00.